| Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS … D Dytfeld, T Wróbel, K Jamroziak, T Kubicki, P Robak, A Walter-Croneck, ... The Lancet Oncology 24 (2), 139-150, 2023 | 30 | 2023 |
| The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients P Robak, I Dróżdż, D Jarych, D Mikulski, E Węgłowska, M Siemieniuk-Ryś, ... Cancers 12 (9), 2569, 2020 | 20 | 2020 |
| Cytokine and chemokine profile in patients with multiple myeloma treated with bortezomib P Robak, E Węgłowska, I Dróżdż, D Mikulski, D Jarych, M Ferlińska, ... Mediators of Inflammation 2020 (1), 1835836, 2020 | 19 | 2020 |
| The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib P Robak, D Jarych, D Mikulski, I Dróżdż, E Węgłowska, A Kotkowska, ... Cancers 13 (5), 951, 2021 | 11 | 2021 |
| OmicSelector: automatic feature selection and deep learning modeling for omic experiments K Stawiski, M Kaszkowiak, D Mikulski, P Hogendorf, A Durczyński, ... BioRxiv, 2022.06. 01.494299, 2022 | 9 | 2022 |
| High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell … D Mikulski, M Nowicki, I Dróźdż, M Misiewicz, KP Kościelny, K Okoński, ... Frontiers in Oncology 13, 1250355, 2023 | 4 | 2023 |
| Risk factors of infection in relapsed/refractory multiple myeloma patients treated with lenalidomide and dexamethasone (Rd) regimen: real-life results of a large single-center … D Mikulski, P Robak, W Ryżewska, K Stańczak, K Kościelny, J Góra-Tybor, ... Journal of Clinical Medicine 11 (19), 5908, 2022 | 4 | 2022 |
| Pretreatment serum levels of IL-1 receptor antagonist and IL-4 are predictors of overall survival in multiple myeloma patients treated with bortezomib D Mikulski, P Robak, E Perdas, E Węgłowska, A Łosiewicz, I Dróżdż, ... Journal of Clinical Medicine 11 (1), 112, 2021 | 4 | 2021 |
| The significance of mRNA in the biology of multiple myeloma and its clinical implications A Puła, P Robak, D Mikulski, T Robak International journal of molecular sciences 22 (21), 12070, 2021 | 4 | 2021 |
| Association of low ficolin-2 concentration in cord serum with respiratory distress syndrome in preterm newborns G Gajek, AS Świerzko, D Jarych, D Mikulski, P Kobiela, K Chojnacka, ... Frontiers in Immunology 14, 1107063, 2023 | 3 | 2023 |
| Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and … D Mikulski, K Kościelny, M Nowicki, E Wawrzyniak, M Kalwas, M Kowalik, ... Leukemia & Lymphoma 64 (1), 98-106, 2023 | 3 | 2023 |
| Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation D Mikulski, I Dróżdż, E Perdas, K Stawiski, M Nowicki, M Misiewicz, ... Blood 138, 4789, 2021 | 3 | 2021 |
| Prognostic value of resistance proteins in plasma cells from multiple myeloma patients treated with bortezomib-based regimens P Robak, J Szemraj, D Mikulski, I Drozdz, K Juszczak, D Jarych, ... Journal of Clinical Medicine 10 (21), 5028, 2021 | 3 | 2021 |
| Jakość życia pacjentów z alergią na jad owadów błonkoskrzydłych odmawiających leczenia za pomocą immunoterapii swoistej. D MIKULSKI, EWA SMORAWSKA-SABANTY, ML KOWALSKI Alergia Astma Immunologia 21 (2), 2016 | 3 | 2016 |
| Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either … T Kubicki, D Dytfeld, T Wróbel, K Jamroziak, P Robak, J Czyż, ... British Journal of Haematology 203 (5), 792-802, 2023 | 2 | 2023 |
| Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone … T Kubicki, D Dytfeld, T Wrobel, K Jamroziak, P Robak, J Czyz, ... Blood 142, 4715, 2023 | 2 | 2023 |
| P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS. A Puła, P Robak, D Jarych, D Mikulski, I Dróżdż, J Szemraj, T Robak HemaSphere 6, 761-762, 2022 | 2 | 2022 |
| Quality of life in patients allergic to Hymenoptera venom who refuse specific immunotherapy D Mikulski, E Smorawska-Sabanty, ML Kowalski ALERGIA ASTMA IMMUNOLOGIA 21 (2), 133-137, 2016 | 2 | 2016 |
| Mass Spectrometry-Based Assessment of M protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma T Kubicki, D Dytfeld, D Barnidge, D Sakrikar, A Przybyłowicz-Chalecka, ... Blood, 2024 | 1 | 2024 |
| Mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial T Kubicki, D Dytfeld, D Barnidge, DJ Sakrikar, G Lakos, ... Blood 142, 340, 2023 | 1 | 2023 |
